Pre-made Cudarolimab benchmark antibody ( Whole mAb, anti-TNFRSF4/CD134 therapeutic antibody, Anti-ACT35/IMD16/OX40/TXGP1L Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-126
Pre-Made Cudarolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cudarolimab (formerly IBI 101) is a recombinant fully human anti-OX40 (tumour necrosis factor receptor superfamily member 4) monoclonal antibody, being developed by Innovent Biologics, for the treatment of various cancers, including solid tumours, and hepatitis B.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
---|---|---|---|---|
GMP-Bios-ab-126-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size: 1mg | 10mg | 100mg
Description
Products Name (INN Index) | Pre-Made Cudarolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody |
INN Name | Cudarolimab |
Target | CD134 |
Format | Whole mAb |
Derivation | |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-I |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2019 |
Year Recommended | 2020 |
Companies | Innovent Biologics |
Conditions Approved | na |
Conditions Active | Solid tumours |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<